TheraRadar
← Back
Data updated: Mar 29, 2026

SUMITOMO PHARMA AM

OncologyNeurologyGastroenterology
Specialty

SUMITOMO PHARMA AM is a specialty pharmaceutical company focused on Oncology, Neurology, Gastroenterology. Key products include MYFEMBREE.

2013
Since
6
Drugs
-
Trials
8
Approved (2yr)

Key Drugs

MYFEMBREE
estradiol
Estrogen receptor 3 indications · 2021
GEMTESA
vibegron
ADRB3 2 indications · 2020
ORGOVYX
relugolix
Oncology
GnRH receptor 1 indications · 2020
APTIOM
eslicarbazepine acetate
Voltage-gated sodium channels 1 indications · 2013

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

ORGOVYX 2025-10-08
Labeling
MYFEMBREE 2025-08-27
Labeling
GEMTESA 2024-12-18
Efficacy
ORGOVYX 2024-10-18
Efficacy
GEMTESA 2024-10-08
Labeling
MYFEMBREE 2024-07-17
Labeling
APTIOM 2024-06-20
Manufacturing (CMC)
MYFEMBREE 2024-04-30
Efficacy
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 63%
1 drugs Phase 3: 4 Phase 2: 6 Phase 1: 17
Neurology 35%
1 drugs Phase 3: 4 Phase 2: 2 Phase 1: 2
Gastroenterology 2%
0 drugs Phase 2: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Bristol-Myers Squibb big-pharma
Oncology, Gastroenterology, Neurology
Takeda big-pharma
Oncology, Gastroenterology, Neurology
Pfizer big-pharma
Oncology, Gastroenterology
Amgen biotech
Oncology, Gastroenterology, Neurology
EMD SERONO INC biotech
Oncology, Neurology, Gastroenterology